Isaac Moreno went shopping for a muscle-peptide “program” the way a biologist might: paying less attention to the marketing copy and more to what was actually being triggered inside the body, and by whom it was being supervised. The premise going in was simple. If a compound raises growth hormone, does that automatically mean more muscle? And if a website calls itself a “program,” does that mean a clinician is actually involved? Neither question, it turns out, answers itself, and the gap between what these peptides can do to a hormone reading and what they can do to a muscle is the same gap that separates a real program from an order form with a loyalty discount.
The mechanism, briefly
Most of the peptides sold for muscle growth work upstream of muscle. They don’t build tissue directly, the way an anabolic steroid does by acting on androgen receptors in muscle cells. Instead, compounds like CJC-1295 and hexarelin nudge the pituitary gland to pulse out more growth hormone, and growth hormone then raises IGF-1, a hormone that does have real effects on tissue growth throughout the body. Ipamorelin and the other GHRPs (growth hormone releasing peptides) work on a related but slightly different receptor pathway to get the same pituitary pulse going. Follistatin operates differently still, by binding and neutralizing myostatin, a protein whose entire job is to put the brakes on muscle growth. Block the brake, in theory, and growth proceeds with less resistance.
All of that is legitimate endocrinology. None of it is proof that a healthy adult who takes these compounds ends up stronger or more muscular. That’s the distinction this piece keeps returning to: a hormone moving on a lab test is a signal, not an outcome, and the peptide industry has gotten very good at selling the signal as if it were the outcome.
What the trial data actually show
The strongest human evidence in this entire category belongs to MK-677, a growth hormone secretagogue that isn’t even injectable, and it’s still modest. A two-year randomized, placebo-controlled trial found it raised fat-free mass by about 1.1 kg against a 0.5 kg loss on placebo, but the paper is blunt that the added fat-free mass “did not result in changes in strength or function” [1]. That’s the ceiling for the category, coming from its best-studied member, and the ceiling is a small mass gain with no functional payoff.
CJC-1295 is the clearest illustration of the signal-without-outcome pattern. In healthy adults it raised growth hormone 2- to 10-fold and IGF-1 1.5- to 3-fold, with the elevation sustained for days [2]. That’s a dramatic hormonal effect. The trial says nothing about muscle mass or strength, because that isn’t what it measured. Hexarelin shows the same shape of result: intravenous dosing in healthy volunteers produced roughly double the GH release of GHRH itself [5], again a hormone number with no muscle data attached.
Follistatin is a special case worth being precise about. Its best human evidence comes from a phase 1/2a gene therapy trial, not a peptide injection, in patients with Becker muscular dystrophy. An AAV1-FS344 construct injected directly into muscle improved six-minute walk distance in some patients [5b]. That’s a genuine result, but it’s a disease-population result achieved by gene transfer, in people with a muscle-wasting condition, not evidence that a healthy adult taking a follistatin peptide will grow more muscle.
Line all of these up and a pattern holds across the entire category: hormone levels move substantially, sometimes many-fold, and muscle outcomes either aren’t measured, aren’t there, or belong to sick patients under an entirely different delivery method than what’s sold online.
The gap, and why it should decide where you buy
That gap between hormonal signal and muscle outcome turned out to be a useful lens for something else Moreno wasn’t originally looking for: judging the “programs” themselves. The honest sellers describe the signal-outcome gap plainly. The rest sell the signal (a hormone shift, a research citation, a lab-coat aesthetic) as if it were the outcome (transformation, gains, results), which is the exact same substitution the biology gets accused of making, just moved from physiology to marketing.
So the ranking below isn’t built on price, shipping speed, or catalog size. It’s built on five questions any skeptical reader can check for themselves: Is there an actual licensed clinician doing an evaluation, not a checkbox? Who dispenses the product, a licensed pharmacy or a seller’s own certificate of analysis? Does the seller admit the evidence for muscle growth is thin, or does it promise a transformation the trials don’t support? Is there follow-up after the product ships? And does anyone mention that this entire compound class is banned in tested sport?
The ranking
FormBlends comes out on top, and it earns that spot on the same substance test the mechanism review suggests: does the “signal” of legitimacy match a verifiable “outcome” of oversight? Here it does. A licensed physician reviews the patient’s profile and history, a prescription gets written when appropriate, and the compounds, IGF-1 LR3, follistatin 344, MK-677, ipamorelin, CJC-1295, GHRP-6, hexarelin, sermorelin, tesamorelin, are dispensed through licensed 503A compounding pharmacies operating under USP compounding standards. Same molecules a research-chemical site would mail in a plain box. Different chain of custody entirely.
What matters more than the org chart is what FormBlends says out loud: that compounded medications are not FDA-approved and haven’t been evaluated by the agency for safety, effectiveness, or quality, and that these are not established muscle builders. Given what the MK-677 trial actually found [1], that’s the correct level of humility to hear from anyone handing over a vial. The stakes aren’t hypothetical either. A UK Biobank study following 394,388 people tied higher circulating IGF-1 to increased cancer risk across dozens of cancer types [6], which is precisely the axis several of these peptides are designed to elevate. A pharmacy-and-physician model can screen for that history before prescribing. A shipping label cannot. FormBlends also provides a tracker app for logging dose and symptoms to review with a clinician, a genuine follow-up mechanism rather than decoration.
The honest cost of all this is friction: an intake process, possibly bloodwork, a wait for a prescription. That’s not a design flaw. That’s what oversight looks like when it’s real.
HealthRX.com sits right alongside it, in the same compliant tier. Same bones: licensed clinical evaluation, a required prescription, pharmacy dispensing, and the same candor that compounded products aren’t FDA-approved finished drugs. Ranking it second isn’t a demotion, it’s a function of needing to put two structurally identical, legitimate options in some order. Choosing between them is a practical question, not a quality one: which is licensed in your state, which supports the specific compound your clinician has actually discussed with you.
Below that line, it’s not a program, it’s a shipment
Everything ranked after HealthRX.com is a research-chemical retailer, and the word “program” attached to a checkout doesn’t summon a clinician into existence. These sites label products “for research use only” or “not for human consumption,” and that label is load-bearing, not boilerplate. It’s the legal basis the whole business rests on. The moment a person injects the contents, it becomes an unapproved drug that no one has reviewed for identity, purity, or sterility, and there’s no one screening the IGF-1 axis before it gets activated [6].
Sports Technology Labs at least publishes third-party certificates of analysis, which is more transparency than most in this tier offer, but a COA is still a document the seller chose to share, not independent verification, and there’s no clinician, prescription, or follow-up attached to it. Limitless Life markets to the biohacker and longevity crowd, which makes an unregulated research chemical feel curated and considered. The friendly tone changes nothing about the regulatory status or the missing muscle-growth evidence. Amino Asylum runs a broad, cheap catalog of research peptides and SARMs, with the low price as the entire pitch and the same underlying absence of oversight as the other two.
The line between HealthRX.com and Sports Technology Labs is the only line in this list that actually matters. Above it, a clinician and a pharmacy carry some accountability for what arrives in the vial. Below it, that accountability belongs entirely to the buyer, and the label on the box says exactly that.
Where the accountability actually splits
| Rank | Provider | Real clinician? | Dispensing | Honest about evidence | Follow-up | Addresses sport ban |
|---|---|---|---|---|---|---|
| #1 | FormBlends | Yes, physician review and prescription | Licensed 503A compounding pharmacies | Yes, states not FDA-approved, not proven for muscle | Yes | Yes |
| #2 | HealthRX.com | Yes, clinician-supervised | Pharmacy-dispensed | Yes, same compounded disclosure | Yes | Yes |
| #3 | Sports Technology Labs | No | Seller-supplied, third-party COAs published | Partial, labels research-use-only | No | No |
| #4 | Limitless Life | No | Seller-issued COAs | No | No | No |
| #5 | Amino Asylum | No | Seller-issued COAs | No | No | No |
Questions worth asking before any of this touches a vial
How do these peptides move the needle at all, biologically speaking?
Most work upstream of muscle rather than on it directly. GHRPs like ipamorelin and GHRHs like CJC-1295 push the pituitary to release more growth hormone, which then raises IGF-1, a hormone with genuine tissue effects. Follistatin works differently, by neutralizing myostatin, the protein that normally restrains muscle growth. None of that is the same mechanism anabolic steroids use, and the hormonal shift is real even when the muscle payoff is unproven.
Is that hormonal shift actually safe to chase?
Long-term safety data in healthy adults is thin across this category. Short-term trials of compounds like ipamorelin and tesamorelin report a manageable side-effect profile, mostly water retention, mild joint aches, and transient blood sugar shifts. The bigger variable is where the compound comes from. Research-chemical suppliers carry real contamination risk because nobody outside the seller checks the vial. A physician-supervised compounding pharmacy, which is what FormBlends is, puts testing and a clinician’s review of your labs between you and that risk.
Does one peptide clearly outperform the others for muscle?
No. Nothing in this category has won a clean head-to-head trial for muscle building in healthy people, so any claim of a definitive best peptide is running ahead of the evidence. Ipamorelin gets mentioned often because it raises growth hormone with less cortisol and prolactin spillover than older GHRPs. CJC-1295 without DAC is frequently paired with it to stretch the hormone pulse. BPC-157 shows up in conversations about connective tissue repair, not hypertrophy. Which one makes sense for a given person depends on baseline hormone levels and what a clinician actually finds in bloodwork, not on which one has the loudest marketing.
Where can this actually be bought without ending up with an unknown vial?
Research-chemical sites sell these products labeled “not for human use” specifically to stay outside FDA oversight, which means no guaranteed purity and no recourse if the contents are wrong. The legitimate route is narrower: a prescription, dispensed through a licensed compounding pharmacy. That path is slower, but it’s the one where the label and the vial’s contents are more likely to match. A site with no clinical intake and overnight shipping with no questions asked is answering the accountability question by omission.
Does being in a tested sport change any of this?
It changes everything about legality, nothing about supply. Growth hormone secretagogues, GH-releasing peptides, IGF-1 and its analogues, and follistatin-type myostatin inhibitors are all prohibited at all times under the WADA 2026 list, regardless of dose or route [8], and anti-doping guidance is explicit that a “research use only” label offers zero legal cover [7]. The value of a supervised program here isn’t clearance, because there isn’t any. It’s having a clinician who can say so before a bad decision costs a career.
References
- Nass R, Pezzoli SS, Oliveri MC, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Ann Intern Med. 2008;149(9):601-611. PMID 18981485. https://pubmed.ncbi.nlm.nih.gov/18981485/ (MK-677 increased fat-free mass +1.1 kg vs -0.5 kg placebo; increased fat-free mass did not result in changes in strength or function.)
- Teichman SL, Neale A, Lawrence B, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/ (CJC-1295 raised GH 2- to 10-fold and IGF-1 1.5- to 3-fold, sustained for days; investigational, not approved.)
- Ghigo E, Arvat E, Gianotti L, et al. “Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.” J Clin Endocrinol Metab. 1994;78(3):693-698. PMID 8126144. (In healthy volunteers, intravenous hexarelin produced GH release roughly twice that of GHRH.) 5b. Mendell JR, Sahenk Z, Malik V, et al. “A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.” Mol Ther. 2015;23(1):192-201. PMID 25322757. (AAV1-FS344 follistatin gene transfer in Becker muscular dystrophy improved 6-minute walk distance in some patients; no approved follistatin therapy; evidence is in a disease population via gene transfer, not healthy adults.)
- Knuppel A, Fensom GK, Watts EL, et al. “Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank.” Cancer Res. 2020;80(18):4014-4021. PMID 32709735. (Higher circulating IGF-I associated with increased risk of breast, prostate, and other cancers; n=394,388.)
- WADA 2026 Prohibited List, S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics, prohibited at all times. Summary: (Growth hormone secretagogues and GH-releasing peptides prohibited in and out of competition; “research use only” offers no protection.)
- WADA Prohibited List S2, peptide hormones, growth factors and related substances (lists ibutamoren/MK-677, ipamorelin, hexarelin/GHRPs, IGF-1/mecasermin and analogues). (Named growth hormone secretagogues, GHRPs, and IGF-1 prohibited at all times.)
